MetaCap

AgomAb Therapeutics NV (AGMB) vs Protalix BioTherapeutics (DE) (PLX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

AgomAb Therapeutics NV is the larger company by market cap ($268.4 million vs $244.5 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

AGMB-62.80%PLX+0.35%
+26%-21%-67%
Feb 6, 20261 yearNov 20, 2026
AGMB-62.80%PLX+0.35%
+13%-27%-66%
Feb 2, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

AGMB versus PLX key metrics
MetricAGMBPLX
Share price$5.45$2.90
Market cap$268.40M$244.52M
1-day change-3.02%-5.23%
YTD return—+61.11%
1-year return—+65.71%
5-year return—+192.93%
P/E ratio (TTM)—12.08
Forward P/E—4.68
EPS (TTM)$-2.08$0.24
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$52.74M
Revenue growth (YoY)—-1.23%
Net income (latest FY)—$-6.60M
Gross margin—48.82%
Operating margin—-10.43%
Net margin—-12.52%
52-week high$17.82$3.19
52-week low$5.39$1.65
Distance from 52-week high-69.42%-9.09%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+591.19%+313.79%
Average volume208.99K903.48K
Shares outstanding49.25M84.32M
Employees62226
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About AgomAb Therapeutics NV

AGMB stock →

AgomAb Therapeutics NV, a clinical-stage biopharmaceutical company, develops novel disease-modifying therapies for immunology and inflammatory diseases in the United States. The company's product pipeline includes Ontunisertib (AGMB-129), an oral gastrointestinal-restricted small molecule inhibitor of ALK5 or TGFßR1 for the treatment of Fibrostenosing Crohn's disease, which is in Phase 2a clinical trials; and AGMB-447, an inhaled small molecule inhibitor of ALK5 or TGFßR1 for the treatment of idiopathic pulmonary fibrosis that is in Phase 1 clinical trials.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 62 employees

About Protalix BioTherapeutics (DE)

PLX stock →

Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company provides Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 226 employees

AGMB vs PLX FAQ

Which is bigger, AgomAb Therapeutics NV or Protalix BioTherapeutics (DE)?

AgomAb Therapeutics NV (AGMB) is larger, with a market capitalization of $268.40M compared with $244.52M for Protalix BioTherapeutics (DE) (PLX).

Are AgomAb Therapeutics NV and Protalix BioTherapeutics (DE) in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons